Alnylam is profitable but stock remains under pressure
Question
Alnylam is profitable but stock remains under pressure
Direct answer
Guidance-cut pressure and demand-normalization concerns can keep ALNY multiple compression in place despite profitability.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-21
- Published
- 2026-10-21
- Revision
- 1 · 2026-10-21
Cite as: Market Ontology, “Alnylam is profitable but stock remains under pressure”, revision 1, evidence through 2026-10-21. https://marketontology.com/market-events/2026-10-21/alnylam-is-profitable-but-stock-remains-under-pressure-2a5f91
How this development reaches the affected companies
| Asset | Exposure and channel | Direction | Evidence |
|---|---|---|---|
| ALNY | multiple compression via revenue-guidance cut and demand normalization | Down1-5d | The decline is attributed to a revenue guidance cut for its drug Amvuttra due to demand normalization. |
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.